Navigating Ongoing Challenges in GI Stromal Tumors

Area of Science:

• Gastroenterology
• Oncology
• Genetics

Background:

• Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms originating in the GI tract, most commonly the stomach.
• GISTs are often driven by oncogenic mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA).
• Treatment strategies have advanced significantly, particularly for GISTs with KIT mutations.

Purpose of the Study:

• To review the current management of GISTs, including surgical resection and adjuvant imatinib therapy.
• To discuss the treatment landscape for advanced GISTs, focusing on tyrosine kinase inhibitors (TKIs) and emerging resistance mechanisms.
• To highlight the challenges and evolving approaches for managing GISTs lacking KIT or PDGFRA mutations.

Main Methods:

• Review of clinical trial data and established treatment guidelines for GISTs.
• Analysis of the efficacy and resistance patterns of various TKIs in advanced GISTs.
• Exploration of genomic and epigenomic alterations driving non-KIT/PDGFRA GISTs.

Main Results:

• Adjuvant imatinib shows benefit in selected GIST patients, with ongoing trials investigating optimal duration.
• TKIs are key for advanced GISTs, but resistance frequently emerges, necessitating novel therapeutic strategies.
• GISTs without KIT/PDGFRA mutations present unique challenges, with distinct biology and reduced responsiveness to current TKIs.

Conclusions:

• Individualized, multidisciplinary, and biology-based management is crucial for all GIST patients.
• Further research into novel treatments and clinical trial enrollment is critical, especially for non-KIT/PDGFRA GISTs.
• Understanding the molecular drivers of GISTs is essential for optimizing patient outcomes.